Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs

J. Smetanova, T. Milota, M. Rataj, J. Hurnakova, H. Zelena, A. Sediva, R. Horvath

. 2022 ; 13 (-) : 1010808. [pub] 20220923

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033280

BACKGROUND: Vaccination confers relatively short-term protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), indicating the need for booster doses. Immunocompromised individuals, including those with immune-mediated inflammatory diseases (IMIDs), may have pronounced immune response waning. Vaccine-boosted humoral and T-cell responses minimize poor coronavirus disease 19 (COVID-19) outcome without increasing adverse events (AE). There is limited evidence of third-dose vaccination in axial spondyloarthritis (AxSpA) patients. We investigated immune-response persistence after primary vaccination and immunogenicity and safety after the BNT162b2 booster vaccination. METHODS: This prospective observational study enrolled an AxSpA cohort treated with interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNFα) inhibitors. Serum SARS-CoV-2-specific and virus-neutralizing antibodies for humoral response and flow cytometric detection of intracellular cytokines following SARS-CoV-2-specific peptide-based stimulation for T-cell immune responses were assessed, and safety was evaluated via a clinical questionnaire. RESULTS: Fifteen male AxSpA patients treated with TNFα (73·3%) or IL-17 (26·7%) inhibitors were enrolled and had humoral response persistence at 6 months: 905·6 ( ± 186·1 SD) and 409·1 ( ± 335·7) U/mL. Specific antibody concentrations further increased after booster vaccination to 989·7 ( ± 12·62) and 1000 U/mL and T-cell responders from 53·3% to 80%, with no differences between AxSpA (including "vaccination only" and "hybrid immunity" subgroups) and healthy control (HC) cohorts. No severe AE occurred; the AE spectrum was comparable to that of the general population. CONCLUSION: Immune-response persistence after primary vaccination and immunogenicity after booster vaccination were unaffected by anti-IL17 or anti-TNFα therapy with similar AE as in the general population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033280
003      
CZ-PrNML
005      
20230131151358.0
007      
ta
008      
230120s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2022.1010808 $2 doi
035    __
$a (PubMed)36211417
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Smetanova, Jitka $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
245    10
$a Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs / $c J. Smetanova, T. Milota, M. Rataj, J. Hurnakova, H. Zelena, A. Sediva, R. Horvath
520    9_
$a BACKGROUND: Vaccination confers relatively short-term protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), indicating the need for booster doses. Immunocompromised individuals, including those with immune-mediated inflammatory diseases (IMIDs), may have pronounced immune response waning. Vaccine-boosted humoral and T-cell responses minimize poor coronavirus disease 19 (COVID-19) outcome without increasing adverse events (AE). There is limited evidence of third-dose vaccination in axial spondyloarthritis (AxSpA) patients. We investigated immune-response persistence after primary vaccination and immunogenicity and safety after the BNT162b2 booster vaccination. METHODS: This prospective observational study enrolled an AxSpA cohort treated with interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNFα) inhibitors. Serum SARS-CoV-2-specific and virus-neutralizing antibodies for humoral response and flow cytometric detection of intracellular cytokines following SARS-CoV-2-specific peptide-based stimulation for T-cell immune responses were assessed, and safety was evaluated via a clinical questionnaire. RESULTS: Fifteen male AxSpA patients treated with TNFα (73·3%) or IL-17 (26·7%) inhibitors were enrolled and had humoral response persistence at 6 months: 905·6 ( ± 186·1 SD) and 409·1 ( ± 335·7) U/mL. Specific antibody concentrations further increased after booster vaccination to 989·7 ( ± 12·62) and 1000 U/mL and T-cell responders from 53·3% to 80%, with no differences between AxSpA (including "vaccination only" and "hybrid immunity" subgroups) and healthy control (HC) cohorts. No severe AE occurred; the AE spectrum was comparable to that of the general population. CONCLUSION: Immune-response persistence after primary vaccination and immunogenicity after booster vaccination were unaffected by anti-IL17 or anti-TNFα therapy with similar AE as in the general population.
650    _2
$a neutralizující protilátky $7 D057134
650    _2
$a protilátky virové $7 D000914
650    12
$a axiální spondyloartritida $7 D000089183
650    _2
$a vakcína BNT162 $7 D000090982
650    12
$a biologické přípravky $7 D001688
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-17 $7 D020381
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a TNF-alfa $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Milota, Tomas $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Rataj, Michal $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Hurnakova, Jana $u Department of Paediatric and Adult Rheumatology, Motol University Hospital, Prague, Czechia
700    1_
$a Zelena, Hana $u Department of Virology, Public Health Institute, Ostrava, Czechia
700    1_
$a Sediva, Anna $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Horvath, Rudolf $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia $u Department of Paediatric and Adult Rheumatology, Motol University Hospital, Prague, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 1010808
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36211417 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151354 $b ABA008
999    __
$a ok $b bmc $g 1891831 $s 1184615
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 13 $c - $d 1010808 $e 20220923 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace